Scoop has an Ethical Paywall
A New Drug For Diabetes Complications Trials
A New Drug For Diabetes Complications Trials
PROTEMIX CORPORATION LTD ANNOUNCES THE COMMENCEMENT OF PHASE II TRIALS OF A NEW DRUG FOR DIABETES COMPLICATIONS.
Protemix Corporation Limited today announced it had started a 12 month Phase II clinical trials programme for drug candidate GC811007. The first trial targets the reversal and prevention of cardiomyopathy in patients with Type 2 diabetes. Concurrent Phase II trials of GC811007 will target safety, pharmacology and diabetic nephropathy
Diabetes afflicts around 140 million people worldwide. The disease is associated with long term complications that affect almost every part of the body. More than 50% of patients with Type 2 diabetes die from the effects of cardiovascular disease. Modern drugs and technology have failed to suppress the progression of diabetes and diabetic complications.
Protemix Corporation Ltd is a New Zealand company dedicated to the discovery and development of novel treatments for diabetes.
ENDS
Worldline: Boxing Day Spending Up On Last Year, But Pre-Christmas Spending Is Slightly Down
Skoltech: Scientists Reinvent Physical Laws Governing Formation Of Snowflakes, Raindrops, And Saturn’s Rings
Trademe: Trash To Treasure - Kiwi Make The Most Of Unwanted Christmas Gifts 
Financial Markets Authority: FMA Seeks Clarity From High Court On Use Of Eligible Investor Certificates In Wholesale Investment Sector
Scion: Scion’s Novel Internship Model Connects Talent With Industry
Financial Markets Authority: Westpac Admits To Misleading Representations That Resulted In $6.35m In Overcharges
